Cowen analyst Phil Nadeau reiterated an Outperform rating on GW Pharmaceuticals (NASDAQ:GWPH) with a price target of $110, following the news that the company’s first Phase …
In a research report issued today, Cowen analyst Ritu Baral reiterated an Outperform rating on Amicus Therapeutics (NASDAQ:FOLD) with a $14 price target, following …
Cowen’s healthcare analyst Eric Schmidt is weighing in with some thoughts on BIND Therapeutics (NASDAQ:BIND), as the company yesterday announced an upbeat strategic overview for 2015, along with …
In a research report published today, Cowen analyst Ritu Baral maintained an Outperform rating on Cempra (NASDAQ:CEMP) and raised his price target to $35 …
In a research report sent to investors today, Cowen analyst Phil Nadeau maintained an Outperform rating on Gilead Sciences (NASDAQ:GILD) with a price …
BlackBerry (NASDAQ:BBRY) released their third quarter fiscal 2015 earnings report on December 19th. The wireless phone and software company continued to report losses …
In a research report released today, Cowen analyst Ritu Baral downgraded shares of Avanir Pharmaceuticals (NASDAQ:AVNR) from Outperform to Market Perform rating, and reduced her price …
Cowen analyst Phil Nadeau maintained an Outperform rating on Dynavax Technologies (NASDAQ:DVAX) and raised his price target to $60 (from $6) to reflect the recent 10:1 reverse …
In a research report issued today, Cowen analyst Boris Peaker reiterated an Outperform rating on Celldex Therapeutics (NASDAQ:CLDX) with a $26 price target. …
Cowen analyst Boris Peaker maintained an Outperform rating on Idera Pharmaceuticals (NASDAQ:IDRA), as the company announced that data for its lead product candidate IMO-8400 …
